Harsha D. Devalla

Dr. Harsha D. Devalla

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2015 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
HDHarsha D. Devalla
Harsha D. Devalla
VSVerena Schwach
Verena Schwach
JFJohn W Ford
John W Ford
JMJames T Milnes
James T Milnes
SESaid El‐Haou
Said El‐Haou
Robert PassierRobert Passier
Robert Passier
Drugs targeting atrial‐specific ion channels, K v 1.5 or K ir 3.1/3.4, are being developed as new therapeutic strategies for atrial fibrillation. However, current preclinical studies carried out in non‐cardiac cell lines or animal models may not accurately represent the physiology of a human cardiomyocyte (CM). In the current study, we tested whether human embryonic stem cell (hESC)‐derived atrial CMs could predict atrial selectivity of pharmacological compounds. By modulating retinoic acid signaling during hESC differentiation, we generated atrial‐like (hESC‐atrial) and ventricular‐like (hESC‐ventricular) CMs. We found the expression of atrial‐specific ion channel genes, KCNA5 (encoding Kv1.5) and KCNJ3 (encoding K ir 3.1), in hESC‐atrial CMs and further demonstrated that these ion channel genes are regulated by COUP‐TF transcription factors. Moreover, in response to multiple ion channel blocker, vernakalant, and K v 1.5 blocker, XEN‐D0101, hESC‐atrial but not hESC‐ventricular CMs showed action potential (AP) prolongation due to a reduction in early repolarization. In hESC‐atrial CMs, XEN‐R0703, a novel K ir 3.1/3.4 blocker restored the AP shortening caused by CCh. Neither CCh nor XEN‐R0703 had an effect on hESC‐ventricular CMs. In summary, we demonstrate that hESC‐atrial CMs are a robust model for pre‐clinical testing to assess atrial selectivity of novel antiarrhythmic drugs.

1 September 2015 in Nature Biotechnology
Verified
Journal Article
Closed access
MBMatthew J Birket
Matthew J Birket
MRMarcelo C Ribeiro
Marcelo C Ribeiro
Arie O. VerkerkArie O. Verkerk
Arie O. Verkerk
DWDorien Ward
Dorien Ward
ALAna Rita Leitoguinho
Ana Rita Leitoguinho
CMChristine L Mummery
Christine L Mummery

24 October 2016 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
HDHarsha D. Devalla
Harsha D. Devalla
RGRoselle Gélinas
Roselle Gélinas
EAElhadi H Aburawi
Elhadi H Aburawi
ABAbdelaziz Beqqali
Abdelaziz Beqqali
PGPhilippe Goyette
Philippe Goyette
Robert PassierRobert Passier
Robert Passier
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

4 April 2018 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
HDHarsha D. Devalla
Harsha D. Devalla
Robert PassierRobert Passier
Robert Passier
Differentiation of human pluripotent stem cells into cardiomyocytes and other cardiac cells enables modeling of heart function and elucidation of disease pathogenesis.

14 October 2021 in Stem Cell Reports
Verified
Journal Article
Open access
AWAlexandra Wiesinger
Alexandra Wiesinger
GBGerard J.J. Boink
Gerard J.J. Boink
VCVincent M. Christoffels
Vincent M. Christoffels
HDHarsha D. Devalla
Harsha D. Devalla
Retinoic acid (RA) signaling plays an important role during heart development in establishing anteroposterior polarity, formation of inflow and outflow tract progenitors, and growth of the ventricular compact wall. RA is also utilized as a key ingredient in protocols designed for generating cardiac cell types from pluripotent stem cells (PSCs). This review discusses the role of RA in cardiogenesis, currently available protocols that employ RA for differentiation of various cardiovascular lineages, and plausible transcriptional mechanisms underlying this fate specification. These insights will inform further development of desired cardiac cell types from human PSCs and their application in preclinical and clinical research.

11 October 2022 in eLife
Verified
Journal Article
Open access
AWAlexandra Wiesinger
Alexandra Wiesinger
JLJiuru Li
Jiuru Li
LFLianne Fokkert
Lianne Fokkert
PBPriscilla Bakker
Priscilla Bakker
Arie O. VerkerkArie O. Verkerk
Arie O. Verkerk
HDHarsha D. Devalla
Harsha D. Devalla
Each heartbeat is triggered by the sinoatrial node (SAN), the primary pacemaker of the heart. Studies in animal models have revealed that pacemaker cells share a common progenitor with the (pro)epicardium, and that the pacemaker cardiomyocytes further diversify into ‘transitional’, ‘tail’, and ‘head’ subtypes. However, the underlying molecular mechanisms, especially of human pacemaker cell development, are poorly understood. Here, we performed single cell RNA sequencing (scRNA-seq) and trajectory inference on human induced pluripotent stem cells (hiPSCs) differentiating to SAN-like cardiomyocytes (SANCMs) to construct a roadmap of transcriptional changes and lineage decisions. In differentiated SANCM, we identified distinct clusters that closely resemble different subpopulations of the in vivo SAN. Moreover, the presence of a side population of proepicardial cells suggested their shared ontogeny with SANCM, as also reported in vivo. Our results demonstrate that the divergence of SANCM and proepicardial lineages is determined by WNT signaling. Furthermore, we uncovered roles for TGFβ and WNT signaling in the branching of transitional and head SANCM subtypes, respectively. These findings provide new insights into the molecular processes involved in human pacemaker cell differentiation, opening new avenues for complex disease modeling in vitro and inform approaches for cell therapy-based regeneration of the SAN.